Eva Giné

44.2k total citations
107 papers, 3.0k citations indexed

About

Eva Giné is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Eva Giné has authored 107 papers receiving a total of 3.0k indexed citations (citations by other indexed papers that have themselves been cited), including 86 papers in Pathology and Forensic Medicine, 55 papers in Genetics and 52 papers in Oncology. Recurrent topics in Eva Giné's work include Lymphoma Diagnosis and Treatment (86 papers), Chronic Lymphocytic Leukemia Research (53 papers) and Viral-associated cancers and disorders (28 papers). Eva Giné is often cited by papers focused on Lymphoma Diagnosis and Treatment (86 papers), Chronic Lymphocytic Leukemia Research (53 papers) and Viral-associated cancers and disorders (28 papers). Eva Giné collaborates with scholars based in Spain, United States and Germany. Eva Giné's co-authors include Elı́as Campo, Neus Villamor, Francesc Bosch, Emili Montserrat, Armando López‐Guillermo, Dolors Colomer, Ana Muntañola, Jordi Esteve, Antonio Martı́nez and Marı́a Rozman and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Neuroscience and Blood.

In The Last Decade

Eva Giné

103 papers receiving 3.0k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Eva Giné	2.0k	1.4k	1.4k	662	461	107	3.0k
Rémy Gressin	1.7k 0.8×	880 0.6×	1.2k 0.9×	561 0.8×	276 0.6×	109	2.5k
Frédéric Davi	2.2k 1.1×	1.7k 1.3×	1.6k 1.1×	1.2k 1.8×	388 0.8×	128	4.2k
Daniela Capello	2.3k 1.1×	1.4k 1.0×	2.1k 1.5×	781 1.2×	293 0.6×	126	3.9k
Elena Hartmann	1.5k 0.7×	1.1k 0.8×	992 0.7×	619 0.9×	276 0.6×	80	2.6k
Mathias Witzens‐Harig	1.1k 0.6×	738 0.5×	1.3k 0.9×	895 1.4×	665 1.4×	136	2.8k
Tanya Siddiqi	1.6k 0.8×	1.0k 0.7×	2.5k 1.8×	777 1.2×	321 0.7×	205	3.5k
Timothy S. Fenske	1.2k 0.6×	624 0.4×	1.7k 1.2×	522 0.8×	543 1.2×	162	2.6k
Alex F. Herrera	2.1k 1.0×	587 0.4×	2.5k 1.8×	642 1.0×	232 0.5×	239	3.5k
Amanda F. Cashen	1.4k 0.7×	549 0.4×	1.0k 0.8×	445 0.7×	891 1.9×	121	2.9k
Robert Redd	1.3k 0.6×	636 0.5×	1.5k 1.1×	888 1.3×	678 1.5×	102	2.7k

Countries citing papers authored by Eva Giné

Since Specialization

Citations

This map shows the geographic impact of Eva Giné's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eva Giné with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eva Giné more than expected).

Fields of papers citing papers by Eva Giné

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eva Giné. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eva Giné. The network helps show where Eva Giné may publish in the future.

Co-authorship network of co-authors of Eva Giné

This figure shows the co-authorship network connecting the top 25 collaborators of Eva Giné. A scholar is included among the top collaborators of Eva Giné based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eva Giné. Eva Giné is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schmidt, Christian, Marek Trněný, Eva Giné, et al.. (2024). Trials in Progress: Carman - an International, Randomized Phase II Study Evaluating Early Treatment Intensification in Patients with High Risk Mantle Cell Lymphoma Using CAR-T-Cell Treatment after an Abbreviated Induction Therapy with Rituximab and Ibrutinib and 6 Months Ibrutinib Maintenance (Arm A) As Compared to Standard of Care Induction and Maintenance (Arm B). Blood. 144(Supplement 1). 4422.3–4422.3. 2 indexed citations

Grande, Carlos, Antonio Gutiérrez, Ángel Ramírez Páyer, et al.. (2024). Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell–like Type: Phase II Clinical Trial of the Spanish GELTAMO Group. Clinical Cancer Research. 30(17). 3704–3714.

Phillips, Tycel, Matthew J. Matasar, Toby A. Eyre, et al.. (2024). MCL-339 GLOBRYTE: A Phase III, Open-label Multicenter, Randomized Trial Evaluating Glofitamab Monotherapy in Patients with Relapsed or Refractory Mantle Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 24. S515–S515. 1 indexed citations

Valero, Juan García, Ferran Nadeu, Renaud Morin, et al.. (2023). A novel patient-derived 3D model recapitulates mantle cell lymphoma lymph node signaling, immune profile and in vivo ibrutinib responses. Leukemia. 37(6). 1311–1323. 17 indexed citations

Balsas, Patricia, Ferran Nadeu, Álvaro Eguileor, et al.. (2022). Tumorigenic role of Musashi-2 in aggressive mantle cell lymphoma. Leukemia. 37(2). 408–421. 4 indexed citations

Balsas, Patricia, Luis Veloza, Guillem Clot, et al.. (2021). SOX11, CD70, and Treg cells configure the tumor immune microenvironment of aggressive mantle cell lymphoma. Blood. 138(22). 2202–2215. 32 indexed citations

Mozas, Pablo, Andrea Rivero, Alfredo Rivas‐Delgado, et al.. (2021). Prognostic ability of five clinical risk scores in follicular lymphoma: A single‐center evaluation. Hematological Oncology. 39(5). 639–649. 5 indexed citations

Demajo, Santiago, Guillem Clot, Giancarlo Castellano, et al.. (2020). A Cyclin D1–Dependent Transcriptional Program Predicts Clinical Outcome in Mantle Cell Lymphoma. Clinical Cancer Research. 27(1). 213–225. 10 indexed citations

Mozas, Pablo, Marc Sorigué, Alfredo Rivas‐Delgado, et al.. (2020). The interval between frontline treatment and the second relapse (PFS2) predicts survival from the second relapse in follicular lymphoma patients. European Journal Of Haematology. 106(3). 428–432. 1 indexed citations

10.

Cid, Joan, et al.. (2020). Role of therapeutic plasma exchanges in refractory severe warm autoimmune hemolytic anemia: Presentation of two case reports. Transfusion. 60(11). 2753–2757. 2 indexed citations

11.

Rivas‐Delgado, Alfredo, Laura Magnano, Olga García, et al.. (2018). Response duration and survival shorten after each relapse in patients with follicular lymphoma treated in the rituximab era. British Journal of Haematology. 184(5). 753–759. 44 indexed citations

12.

Matas‐Céspedes, Alba, Vanina Rodríguez, Neus Villamor, et al.. (2016). The Human CD38 Monoclonal Antibody Daratumumab Shows Antitumor Activity and Hampers Leukemia–Microenvironment Interactions in Chronic Lymphocytic Leukemia. Clinical Cancer Research. 23(6). 1493–1505. 45 indexed citations

13.

Rovira, Jordina, Kennosuke Karube, Alexandra Valera, et al.. (2016). MYD88 L265P Mutations, But No Other Variants, Identify a Subpopulation of DLBCL Patients of Activated B-cell Origin, Extranodal Involvement, and Poor Outcome. Clinical Cancer Research. 22(11). 2755–2764. 50 indexed citations

14.

Dlouhy, Iván, Sabela Lens, Jordina Rovira, et al.. (2016). Clinico-biological characteristics and outcome of hepatitis C virus-positive patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Annals of Hematology. 96(3). 405–410. 12 indexed citations

15.

Matas‐Céspedes, Alba, Vanina Rodríguez, Susana G. Kalko, et al.. (2014). Disruption of Follicular Dendritic Cells–Follicular Lymphoma Cross-talk by the Pan-PI3K Inhibitor BKM120 (Buparlisib). Clinical Cancer Research. 20(13). 3458–3471. 21 indexed citations

16.

Muntañola, Ana, Sónia Rodríguez, & Eva Giné. (2014). Varón de 28 años con hepatoesplenomegalia y fiebre. Medicina Clínica. 143(6). 261–267.

17.

Fayad, Luis, Fritz Offner, Mitchell R. Smith, et al.. (2013). Safety and Clinical Activity of a Combination Therapy Comprising Two Antibody-Based Targeting Agents for the Treatment of Non-Hodgkin Lymphoma: Results of a Phase I/II Study Evaluating the Immunoconjugate Inotuzumab Ozogamicin With Rituximab. Journal of Clinical Oncology. 31(5). 573–583. 119 indexed citations

18.

Baptista, Maria João, Ana Muntañola, Pau Abrisqueta, et al.. (2012). Differential Gene Expression Profile Associated to Apoptosis Induced by Dexamethasone in CLL Cells According to IGHV/ZAP-70 Status. Clinical Cancer Research. 18(21). 5924–5933. 4 indexed citations

19.

Advani, Anjali S., Bertrand Coiffier, Myron S. Czuczman, et al.. (2010). Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study. Journal of Clinical Oncology. 28(12). 2085–2093. 255 indexed citations

20.

Verhoef, Gregor, Mitchell R. Smith, Peter Johnson, et al.. (2010). Anti-CD22 immunoconjugate inotuzumab ozogamicin (CMC-544) + rituximab: clinical activity in patients with relapsed/refractory follicular or 'aggressive' lymphoma. Ghent University Academic Bibliography (Ghent University). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact